The Baseline Tumor Size is an independent prognostic Factor for the progression-free but not the Overall Survival after Ipilimumab in Patients with metastatic malignant Melanoma

被引：0
|
作者：
Angelova, D. [1 ]
Weide, B. [2 ]
Heppt, M. [3 ]
Berking, C. [3 ]
Tietze, J. [1 ]
机构：
[1] Klinikum Augsburg, Dermatol, Augsburg, Germany
[2] Univ Hautklin Tubingen, Dermatol, Tubingen, Germany
[3] Ludwig Maximilians Univ Munchen, Dermatol, Munich, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2018年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P125
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [31] Malignant melanoma: overall survival after combined nivolumab ipilimumab therapy
    Krome, Susanne
    AKTUELLE DERMATOLOGIE, 2018, 44 (03) : 87 - 87
  • [32] Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization
    Alexa O. Levey
    Mohammad Elsayed
    David H. Lawson
    Robert M. Ermentrout
    Ragini R. Kudchadkar
    Zachary L. Bercu
    Melinda L. Yushak
    Janice Newsome
    Nima Kokabi
    CardioVascular and Interventional Radiology, 2020, 43 : 254 - 263
  • [33] Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization
    Levey, Alexa O.
    Elsayed, Mohammad
    Lawson, David H.
    Ermentrout, Robert M.
    Kudchadkar, Ragini R.
    Bercu, Zachary L.
    Yushak, Melinda L.
    Newsome, Janice
    Kokabi, Nima
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2020, 43 (02) : 254 - 263
  • [34] Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
    Beauchemin, Catherine
    Cooper, Dan
    Lapierre, Marie-Eve
    Yelle, Louise
    Lachaine, Jean
    ONCOTARGETS AND THERAPY, 2014, 7 : 1101 - 1110
  • [35] Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer
    McGarrah, Patrick
    Hubbard, Joleen
    Novotny, Paul J.
    Branda, Megan E.
    Sargent, Daniel S.
    Morton, Roscoe F.
    Fuchs, Charles S.
    Benson, Al B.
    Williamson, Stephen K.
    Findlay, Brian P.
    Alberts, Steven R.
    Goldberg, Richard M.
    Sloan, Jeff A.
    CANCER CONTROL, 2023, 30
  • [36] Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
    Morgane Caulet
    Thierry Lecomte
    Olivier Bouché
    Jérôme Rollin
    Valérie Gouilleux-Gruart
    Nicolas Azzopardi
    Julie Léger
    Christophe Borg
    Jean-Yves Douillard
    Sylvain Manfredi
    Denis Smith
    Olivier Capitain
    Aurélie Ferru
    Driffa Moussata
    Eric Terrebone
    Gilles Paintaud
    David Ternant
    Clinical Pharmacokinetics, 2016, 55 : 1381 - 1394
  • [37] Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
    Caulet, Morgane
    Lecomte, Thierry
    Bouche, Olivier
    Rollin, Jerome
    Gouilleux-Gruart, Valerie
    Azzopardi, Nicolas
    Leger, Julie
    Borg, Christophe
    Douillard, Jean-Yves
    Manfredi, Sylvain
    Smith, Denis
    Capitain, Olivier
    Ferru, Aurelie
    Moussata, Driffa
    Terrebone, Eric
    Paintaud, Gilles
    Ternant, David
    CLINICAL PHARMACOKINETICS, 2016, 55 (11) : 1381 - 1394
  • [38] VE-CADHERIN IN MULTIPLE MYELOMA: AN INDEPENDENT PROGNOSTIC FACTOR FOR PROGRESSION-FREE SURVIVAL
    Samura, B.
    Kolesnyk, Y.
    Syvolap, V.
    Abramov, A.
    HAEMATOLOGICA, 2017, 102 : 796 - 797
  • [39] Re: Validation of Serum Amyloid α as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients
    Laguna, M. Pilar
    JOURNAL OF UROLOGY, 2013, 189 (03): : 840 - 841
  • [40] Prognostic Factors for Progression-free Survival and Overall Survival Αfter Recurrence of Glioblastoma
    Zemskova, Oksana
    Yu, Nathan y.
    Leppert, Jan
    Rades, Dirk
    ANTICANCER RESEARCH, 2024, 44 (07) : 3059 - 3066
12345